Mikhail Zibinsky

Mikhail Zibinsky is a highly experienced professional in the pharmaceutical and biotechnology sectors, currently serving as a Director at Septerna since July 2025, and previously held the position of Director at RAPT Therapeutics from April 2015 to July 2025, focusing on targets related to undisclosed inflammatory diseases. Mikhail has a strong background in drug discovery, having served as Principal Investigator for the development of Zelnecinon (RPT193), a CCR4 antagonist for inflammation currently in phase II, and as a Scientist for the discovery of Tivumecirnon (FLX475), also a CCR4 antagonist targeting cancer, currently in phase II. Mikhail's earlier work includes significant contributions to cancer research at Flexus Biosciences, where Linrodostat (BMS986205 / FLX287), an IDO1 inhibitor, was developed. Mikhail's educational credentials include a Ph.D. in Chemistry from the University of Southern California and a B.S. in Computer Science and Chemistry from St. Petersburg State University.